Diatech Pty. Ltd.

A Vipep Pty Limited

Adalta Pty Ltd.

Anaptysbio, Inc.

Quintain Consulting Pty Ltd

Peter John Hudson

Robert Alexander Irving

Debra Tamvakis

Fabio Turatti

Michael P Wheatcroft

Stewart Douglas Nuttall

Maria Galanis

Michael Paul Wheatcroft

Gregory Coia

David Leong

Peter Iliades

Kylie Anne Henderson

David Peter Simmons

Joseph Noozhumurry Varghese

Jennifer Ann Carmichael

Katherine Merne Griffiths

Victor Streltsov

Stewart Nuttal

Paul R Sanders

Miles Mackay Barraclough

Huseyin Mustafa

Matias Ezequiel Abregu

Kim Wark

Joseph Noozhumutry Varghese

Paul Robert Sanders

The present invention provides an isolated protein comprising an immunoglobulin variable region comprising at least two cysteine residues positioned within framework region (FR) 2 and/or at least two cysteine residues positioned within framework region (FR3), wherein if at least two of the cysteine residues in FR2 and/or FR3 are not conjugated to a compound then an intra-framework disulphide bond is capable of forming between the cysteine residues. Preferably the protein comprises an immunoglobulin heavy chain variable region (V) and an immunoglobulin light chain variable region (V), wherein at least one of the variable regions comprises the two cysteine residues. The present invention also provides conjugates of the protein and another compound.

Immuno-conjugates and methods for producing them

The present invention provides an isolated protein comprising an immunoglobulin variable region comprising at least two cysteine residues positioned within framework region 1 such that if at least two of the cysteine residues are not conjugated to another compound a disulphide bond forms between the cysteine residues. Preferably the protein comprises an immunoglobulin heavy chain variable region and an immunoglobulin light chain variable region, wherein at least one of the variable regions comprises the two cysteine residues. The present invention also provides a protein that binds to TAG72. The present invention also provides conjugates of the protein and another compound.

The present invention relates to immunoglobulin new antigen receptors (IgNARs) from fish and uses thereof. In particular, the present invention relates to modified IgNAR variable domains and to domains from members of the immunoglobulin superfamily that have been modified to include structural features derived from IgNAR variable domains.

Binding moieties based on shark ignar domains

The present invention relates to binding moieties comprising at least one monomeric V-like domain (VLD) derived from a non-antibody ligand, the at least one monomeric V-like domain being characterised in that at least one CDR loop structure or part thereof is modified or replaced such that the solubility of the modified VLD is improved when compared with the unmodified VLD.

V-like domain binding molecules and polynucleotides encoding therefor

The present invention relates to binding moieties comprising at least one monomeric V-like domain (VLD) derived from a non-antibody ligand, the at least one monomeric V-like domain being characterized in that at least one CDR loop structure or part thereof is modified or replaced such that the solubility of the modified VLD is improved when compared with the unmodified VLD.

V-like domain binding molecules

The present invention provides a method for the mutation, synthesis and selection of a protein which binds to a target molecule, the method comprising: (a) incubating a replicable mRNA molecule encoding the protein with ribonucleoside triphosphate precursors of RNA and an RNA-directed RNA polymerase, wherein the RNA-directed RNA polymerase replicates the mRNA molecule but introduces mutations thereby generating a population of mutant mRNA molecules; (b) incubating the mutant mRNA molecules from step (a) with a translation system under conditions which results in the synthesis of population of mutant proteins such that after translation, mutant proteins are linked to their encoding mRNA molecules thereby forming a population of mutant proteins such that after translation, mutant proteins are linked to their encoding mRNA molecules thereby forming a population of mutant/mRNA complexes; (c) selecting one or more mutant protein/mRNA complex(es) by exposing the population of mutant protein/mRNA complexes from step (b) to the target molecule and recovering the mutant protein/mRNA complex(es) bound thereto.

Continuous in vitro evolution

Growing community of inventors

Blackburn, Australia

Peter John Hudson